Chembio Diagnostics, Inc. (CEMI): Price and Financial Metrics

Chembio Diagnostics, Inc. (CEMI): $0.46

0.00 (0.22%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

CEMI Price/Volume Stats

Current price $0.46 52-week high $1.24
Prev. close $0.45 52-week low $0.19
Day low $0.45 Volume 351,600
Day high $0.46 Avg. volume 661,416
50-day MA $0.43 Dividend yield N/A
200-day MA $0.45 Market Cap 16.71M

CEMI Stock Price Chart Interactive Chart >


Chembio Diagnostics, Inc. (CEMI) Company Bio


Chembio Diagnostics, Inc., together with its wholly-owned subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures, markets, and licenses rapid point-of-care (POC) diagnostic tests that detect infectious diseases. The company was founded in 1985 and is based in Medford, New York.


CEMI Latest News Stream


Event/Time News Detail
Loading, please wait...

CEMI Latest Social Stream


Loading social stream, please wait...

View Full CEMI Social Stream

Latest CEMI News From Around the Web

Below are the latest news stories about CHEMBIO DIAGNOSTICS INC that investors may wish to consider to help them evaluate CEMI as an investment opportunity.

Biosynex Completes Acquisition of Chembio Diagnostics, Inc.

Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced it has completed its acquisition of Chembio Diagnostics, Inc. (“Chembio”), a leading point-of-care diagnostics company focused on infectious diseases. Chembio is now part of Biosynex Group. The comp

Yahoo | April 27, 2023

Chembio Stockholders Urged to Tender Shares Before 6:00 P.M., New York City Time, on April 26, 2023

Failure to tender shares could result in the termination of the proposed merger between Chembio and BiosynexMEDFORD, N.Y., April 19, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 19, 2023 Fellow Chembio Stockholders, We strongly urge you to tender your shares of common stock of Chembio Diagno

Yahoo | April 19, 2023

Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.

STRASBOURG, France, April 13, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that Project Merci Merger Sub, Inc. (“Purchaser”), a Nevada corporation and its wholly-owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the “Shares”) of Chembio Diagnostics, Inc. (Nasd

Yahoo | April 13, 2023

Chembio Stockholders Reminded to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023

MEDFORD, N.Y., April 10, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 10, 2023 Fellow Chembio Stockholders, As previously communicated, Chembio Diagnostics, Inc. (“Chembio” or the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”), dated as of January 31, 2023,

Yahoo | April 10, 2023

Chembio’s CEO Letter to Stockholders

Reminder to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023MEDFORD, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 3, 2023 Fellow Chembio Stockholders, As previously communicated, Chembio Diagnostics, Inc. (“Chembio” or the “Company”) entered into an Agree

Yahoo | April 3, 2023

Read More 'CEMI' Stories Here

CEMI Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 31.43%
3-year -89.00%
5-year -91.83%
YTD N/A
2023 0.00%
2022 -80.73%
2021 -76.00%
2020 4.17%
2019 -19.43%

Continue Researching CEMI

Want to see what other sources are saying about Chembio Diagnostics Inc's financials and stock price? Try the links below:

Chembio Diagnostics Inc (CEMI) Stock Price | Nasdaq
Chembio Diagnostics Inc (CEMI) Stock Quote, History and News - Yahoo Finance
Chembio Diagnostics Inc (CEMI) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!